ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus
PR Newswire•12/10/2026•16:30 ET
0
Key Highlights
- ➤TissueCypher identified 62% five-year progression risk in a presumed low-risk NDBE patient
- ➤Repeat endoscopy found previously missed high-grade dysplasia after TissueCypher high-risk result
- ➤Multi-center study changed management recommendations for 96% of tested patients
- ➤TissueCypher classified 17% of patients as intermediate/high risk versus 69% under PIB scoring
- ➤TissueCypher high-risk result indicated 47% five-year progression risk in a complex biopsy case
Expert Statements
Virendra Joshi, M.D., FAGA, FACG, board-certified gastroenterologist and associate professor, Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine
“Endoscopic biopsy findings do not always tell the whole story when it comes to a patient's risk of progression”
Virendra Joshi, M.D., FAGA, FACG, board-certified gastroenterologist and associate professor, Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine
“The studies being presented at ACG demonstrate how TissueCypher can complement standard pathology by providing objective molecular risk information that helps guide surveillance and treatment decisions for patients with Barrett's esophagus, particularly when a patient's molecular risk suggests a different approach than their biopsy diagnosis alone would indicate.”
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus PR Newswire
Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings alone
Get started
Create a free account to read the full story.